CSCallie Smith

Callie Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Callie Smith has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation

    by Lorin Adams, Phoebe Stevenson‐Leggett, Jia Le Lee, James Bazire, Giulia Dowgier, Agnieszka Hobbs, Chloë Roustan, Annabel Borg, Christine Carr, Silvia Innocentin, et al.

    Background: Influenza remains a significant threat to human and animal health. Assessing serological protection against influenza has relied upon haemagglutinin inhibition (HAI) assays, which are used to gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology studies. HAI assays were first described in the 1940s. Here, we adapt our high‐throughput live virus microneutralisation (LV‐N) assay for SARS‐CoV‐2, benchmark against HAI assays, and report serological vaccine responsiveness in a cohort of older (> 65 yo) community dwelling adults.Methods: Influenza‐specific antibody responses were assessed in 73 individuals, before and after receipt of the adjuvanted 2021–22 Northern Hemisphere quadrivalent vaccine. We performed both HAI and LV‐N assays against all four viruses represented in the vaccine [A/Cambodia/e0826360/2020 (H3N2), IVR‐215 (A/Victoria/2570/2019‐like) (H1N1)pdm09, B/Phuket/3073/2013 (B/Yamagata lineage), B/Washington/02/2019 (B/Victoria lineage)], using sera drawn before vaccination [range: d‐82 to d‐5], and days 7 [d6–10] and 181 [d156–200] after vaccination. We compared serological responses within each assay and between assays.Results: Both the traditional HAI assay and our high‐throughput live virus microneutralisation identified vaccine‐induced boosts in antibody titres. We found population‐level concordance between the two assays (Spearman's correlation coefficient range 0.49–0.88; all p ≤ 1.4 × 10−5). The improved granularity of microneutralisation was better able to estimate fold changes of responses and quantify the inhibitory effect of pre‐existing antibody.Conclusions: Our high‐throughput method offers an alternative approach to assess influenza‐specific serological responses with improved resolution, with the potential to improve the annual assessment of existing antibody landscapes, to improve new vaccine strain evaluation, and to offer a step‐change in systems vaccinology, and a facet of laboratory‐based pandemic preparedness.


  • Open Access

    COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history

    by Hermaleigh Townsley, Joshua Gahir, Timothy W. Russell, David Greenwood, Edward J. Carr, Matala Dyke, Lorin Adams, Murad Miah, Bobbi Clayton, Callie Smith, et al.

    Background: SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms and viral loads over the course of COVID-19 infection with these sub-variants in otherwise-healthy, vaccinated, non-hospitalised adults, and compared data to infections with the preceding Delta variant of concern (VOC). Methods: In a prospective, observational cohort study, healthy vaccinated UK adults who reported a positive polymerase chain reaction (PCR) or lateral flow test, self-swabbed on alternate weekdays until day 10. We compared participant-reported symptoms and viral load trajectories between infections caused by VOCs Delta and Omicron (sub-variants BA.1, BA.2 or BA.4/5), and tested for relationships between vaccine dose, symptoms and PCR cycle threshold (Ct) as a proxy for viral load using Chi-squared (χ2) and Wilcoxon tests. Results: 563 infection episodes were reported among 491 participants. Across infection episodes, there was little variation in symptom burden (4 [IQR 3–5] symptoms) and duration (8 [IQR 6–11] days). Whilst symptom profiles differed among infections caused by Delta compared to Omicron sub-variants, symptom profiles were similar between Omicron sub-variants. Anosmia was reported more frequently in Delta infections after 2 doses compared with Omicron sub-variant infections after 3 doses, for example: 42% (25/60) of participants with Delta infection compared to 9% (6/67) with Omicron BA.4/5 (χ2 P < 0.001; OR 7.3 [95% CI 2.7–19.4]). Fever was less common with Delta (20/60 participants; 33%) than Omicron BA.4/5 (39/67; 58%; χ2 P = 0.008; OR 0.4 [CI 0.2–0.7]). Amongst infections with an Omicron sub-variants, symptoms of coryza, fatigue, cough and myalgia predominated. Viral load trajectories and peaks did not differ between Delta, and Omicron, irrespective of symptom severity (including asymptomatic participants), VOC or vaccination status. PCR Ct values were negatively associated with time since vaccination in participants infected with BA.1 (β = -0.05 (CI -0.10–0.01); P = 0.031); however, this trend was not observed in BA.2 or BA.4/5 infections. Conclusion: Our study emphasises both the changing symptom profile of COVID-19 infections in the Omicron era, and ongoing transmission risk of Omicron sub-variants in vaccinated adults. Trial registration: NCT04750356.